Clinical characteristics of Burkitt-like lymphoma and diffuse large B-cell lymphoma
| Characteristic . | BLL . | DLBCL . |
|---|---|---|
| Male: female ratio | 3.3:1 | 1.6:1 |
| Median (range) age, y | 47 (28–69) | 58 (29–87) |
| 60 y of age or older | 10 | 33 |
| International prognostic index risk group | ||
| Low | 30 | 15 |
| Low-intermediate | 50 | 30 |
| High-intermediate | 10 | 39 |
| High | 10 | 15 |
| Stage of disease | ||
| Stage I or nonbulky II | 30 | 24 |
| Bulky stage II, III, or IV | 70 | 76 |
| Poor performance status | 0 | 18 |
| Increased lactate dehydrogenase | 90 | 79 |
| 2 or more extranodal sites involved | 60 | 70 |
| Median survival, y | 1.2 | 2.5 |
| Characteristic . | BLL . | DLBCL . |
|---|---|---|
| Male: female ratio | 3.3:1 | 1.6:1 |
| Median (range) age, y | 47 (28–69) | 58 (29–87) |
| 60 y of age or older | 10 | 33 |
| International prognostic index risk group | ||
| Low | 30 | 15 |
| Low-intermediate | 50 | 30 |
| High-intermediate | 10 | 39 |
| High | 10 | 15 |
| Stage of disease | ||
| Stage I or nonbulky II | 30 | 24 |
| Bulky stage II, III, or IV | 70 | 76 |
| Poor performance status | 0 | 18 |
| Increased lactate dehydrogenase | 90 | 79 |
| 2 or more extranodal sites involved | 60 | 70 |
| Median survival, y | 1.2 | 2.5 |
Values are percentages of cases unless otherwise indicated. BLL indicates Burkitt-like lymphoma; DLBCL, diffuse large B-cell lymphoma.